The abstract states that exercise remains the primary therapeutic modality and new treatment targets are needed, implying failure of other interventions. The mechanistic basis for why IBM resists most therapeutic approaches while responding to exercise is not explained, limiting rational drug development. Gap type: open_question Source paper: Inclusion body myositis: an update. (2025, Current opinion in rheumatology, PMID:39469805)
Landscape Summary: Why do current therapeutic approaches beyond exercise show limited efficacy in IBM treatment? is a 0.82 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
Why do current therapeutic approaches beyond exercise show limited efficacy in IBM treatment? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: